• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals (NQ: IONS )

    37.86 -0.05 (-0.13%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,579,297
    Open 37.74
    Bid (Size) 37.10 (1)
    Ask (Size) 39.20 (3)
    Prev. Close 37.91
    Today's Range 37.57 - 38.06
    52wk Range 35.95 - 54.44
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
    Via Benzinga
    Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -28.39%
    -28.39%
    1 Month
    -21.66%
    -21.66%
    3 Month
    -19.86%
    -19.86%
    6 Month
    -10.37%
    -10.37%
    1 Year
    -18.48%
    -18.48%

    More News

    Read More
    Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
    Via Benzinga
    12 Analysts Have This To Say About Ionis Pharmaceuticals
    Via Benzinga
    Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
    From Biogen Inc.
    Via GlobeNewswire
    Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
    Via Benzinga
    Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
    Via Investor's Business Daily
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga
    Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Masters In Trading - Saturday, June 22
    Via Talk Markets
    Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
    Via Benzinga
    Exposures Product Safety
    Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
    Via Benzinga
    Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
    Via Benzinga
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
    From Biogen Inc.
    Via GlobeNewswire
    The 3 Most Undervalued Pharma Stocks to Buy in May 2024
    Via InvestorPlace
    IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
    Via Benzinga
    Are These 5 Undervalued Stocks Ready to Break Out?
    Via MarketBeat
    New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
    From Biogen Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.